# A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct01042769` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01042769](<https://clinicaltrials.gov/study/NCT01042769>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01042769

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 7226 participants.

## Technical summary

Registry record NCT01042769. Randomized; double masking; primary purpose treatment. Start 2010-02 (registry gives no type); primary completion 2013-11 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 7226 participants (enrolled count; ClinicalTrials.gov record NCT01042769, source copy `cardio:ctgov-nct01042769-2016-11-02`, retrieved 2026-10-26)
- Start date: 2010-02 (registry gives no type) (ClinicalTrials.gov record NCT01042769, source copy `cardio:ctgov-nct01042769-2016-11-02`, retrieved 2026-10-26)
- Primary completion: 2013-11 (actual) (ClinicalTrials.gov record NCT01042769, source copy `cardio:ctgov-nct01042769-2016-11-02`, retrieved 2026-10-26)
- Completion: 2013-11 (actual) (ClinicalTrials.gov record NCT01042769, source copy `cardio:ctgov-nct01042769-2016-11-02`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Brazil; Canada; China; Czechia; Denmark; France; Germany; Grenada; Hungary; India; Ireland; Italy; Malaysia; Mexico; Netherlands; New Zealand; Poland; Romania; Russia; South Korea; Spain; Sweden; Thailand; United Kingdom (ClinicalTrials.gov record NCT01042769, source copy `cardio:ctgov-nct01042769-2016-11-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01042769-2016-11-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
- Condition: Diabetes Mellitus Type 2
- Intervention (Drug): Aleglitazar
- Intervention (Drug): Placebo
- Lead sponsor: Hoffmann-La Roche
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Hoffmann-La Roche (`cardio:org-hoffmann-la-roche`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial (`cardio:pubmed-24682069`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome (`cardio:pubmed-29903845`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 3b06c9ff67c1543ed489f9e26172af8dc0f2d3706b033f14bd6b4db60d99b181
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
